JP6887987B2 - Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ - Google Patents

Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ Download PDF

Info

Publication number
JP6887987B2
JP6887987B2 JP2018508748A JP2018508748A JP6887987B2 JP 6887987 B2 JP6887987 B2 JP 6887987B2 JP 2018508748 A JP2018508748 A JP 2018508748A JP 2018508748 A JP2018508748 A JP 2018508748A JP 6887987 B2 JP6887987 B2 JP 6887987B2
Authority
JP
Japan
Prior art keywords
nlrp3
expression
asc
analog
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018508748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523687A (ja
JP2018523687A5 (https=
Inventor
ブラウン・ザ・サード，カール・オスカー
チェン，チー−クワン
リー，ジン−イー
ルゥ，ウェイ−シュウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TWi Biotechnology Inc
Original Assignee
TWi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TWi Biotechnology Inc filed Critical TWi Biotechnology Inc
Publication of JP2018523687A publication Critical patent/JP2018523687A/ja
Publication of JP2018523687A5 publication Critical patent/JP2018523687A5/ja
Priority to JP2021083646A priority Critical patent/JP2021121605A/ja
Application granted granted Critical
Publication of JP6887987B2 publication Critical patent/JP6887987B2/ja
Priority to JP2023045240A priority patent/JP2023078360A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018508748A 2015-08-17 2016-08-17 Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ Active JP6887987B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021083646A JP2021121605A (ja) 2015-08-17 2021-05-18 Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ
JP2023045240A JP2023078360A (ja) 2015-08-17 2023-03-22 Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562206102P 2015-08-17 2015-08-17
US62/206,102 2015-08-17
PCT/US2016/047272 WO2017031161A1 (en) 2015-08-17 2016-08-17 Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021083646A Division JP2021121605A (ja) 2015-08-17 2021-05-18 Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ

Publications (3)

Publication Number Publication Date
JP2018523687A JP2018523687A (ja) 2018-08-23
JP2018523687A5 JP2018523687A5 (https=) 2019-09-19
JP6887987B2 true JP6887987B2 (ja) 2021-06-16

Family

ID=58051269

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018508748A Active JP6887987B2 (ja) 2015-08-17 2016-08-17 Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ
JP2021083646A Pending JP2021121605A (ja) 2015-08-17 2021-05-18 Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ
JP2023045240A Pending JP2023078360A (ja) 2015-08-17 2023-03-22 Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021083646A Pending JP2021121605A (ja) 2015-08-17 2021-05-18 Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ
JP2023045240A Pending JP2023078360A (ja) 2015-08-17 2023-03-22 Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ

Country Status (13)

Country Link
US (1) US10195170B2 (https=)
EP (2) EP3337782A4 (https=)
JP (3) JP6887987B2 (https=)
KR (1) KR20180037261A (https=)
CN (1) CN108349867B (https=)
AU (2) AU2016308121A1 (https=)
BR (1) BR112018003212A2 (https=)
CA (1) CA2994987C (https=)
IL (1) IL257379A (https=)
MX (1) MX2018002049A (https=)
RU (1) RU2729066C2 (https=)
TW (1) TWI743047B (https=)
WO (1) WO2017031161A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
EP3562506A4 (en) 2016-12-29 2021-01-06 University of Miami METHOD TO MODULATE INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG
CN110177547B (zh) 2017-01-18 2022-09-27 台睿生物科技股份有限公司 用于治疗炎症性肠病和肠结肠炎的组合物
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
JP2020530472A (ja) * 2017-08-11 2020-10-22 オラテック セラピューティクス リミティド ライアビリティ カンパニー シュニッツラー症候群の治療方法
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2020010273A1 (en) 2018-07-03 2020-01-09 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
KR102075724B1 (ko) * 2018-09-14 2020-02-10 한국원자력의학원 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도
IL283127B1 (en) 2018-11-14 2026-02-01 Smilebiotek Zhuhai Ltd Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders
ES2975968T3 (es) * 2018-12-03 2024-07-18 Smilebiotek Zhuhai Ltd Galato de octilo y ésteres del mismo para uso en el tratamiento y prevención de la degeneración macular asociada a la edad causada por Bacillus Megaterium
EA202191968A1 (ru) 2019-01-14 2021-11-16 Кадила Хелзкэр Лимитед Новые замещенные производные сульфонилмочевины
CN109833292A (zh) * 2019-02-23 2019-06-04 河南省人民医院 一种双醋瑞因滴眼液及其用途
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN110179865A (zh) * 2019-06-26 2019-08-30 广州中医药大学(广州中医药研究院) 一种大黄蒽醌类成分的制备方法及其应用
CN110787157A (zh) * 2019-11-27 2020-02-14 中南民族大学 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用
JP7072260B2 (ja) * 2019-12-27 2022-05-20 国立大学法人愛媛大学 マックル・ウェルズ症候群の治療用医薬組成物
JP7459298B2 (ja) * 2020-01-06 2024-04-01 シーサン・セラピューティクス 細胞透過性核酸複合体を有効成分として含有する黄斑変性の予防又は治療用組成物
CN111358950A (zh) * 2020-03-20 2020-07-03 厦门大学 Caspase-1及ASC/Caspase-8作为靶点的应用
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022084300A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring form of coronavirus infection
CN115616216B (zh) * 2021-07-15 2025-08-12 华南理工大学 抑制或阻断faah与nlrp3之间相互作用的制剂的用途
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128317A1 (en) 2001-01-23 2002-09-12 Laboratories Negma Treatment of pathological conditions characterized by an increased IL-1 level
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
GB0404953D0 (en) * 2004-03-04 2004-04-07 Arakis Ltd Pro-drugs
EP2300000A1 (en) * 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
CN102060809B (zh) * 2009-05-01 2015-05-20 常州高新技术产业开发区三维工业技术研究所有限公司 一种大黄酸衍生物及其制备和用途
NZ602583A (en) * 2010-04-08 2014-10-31 Twi Biotechnology Inc Methods of using diacerein as an adjunctive therapy for diabetes
WO2012013670A1 (en) * 2010-07-29 2012-02-02 University Of Geneva Process for the esterification of hyaluronic acid with hydrophobic organic compounds
WO2012125359A1 (en) * 2011-03-11 2012-09-20 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
WO2013007763A1 (en) * 2011-07-12 2013-01-17 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
US8652540B2 (en) * 2012-06-04 2014-02-18 Hong Kong Baptist University Method of using rhein for treating fibrotic conditions and tumors
CN103110617A (zh) * 2013-03-22 2013-05-22 中国人民解放军肾脏病研究所 一种双醋瑞因在制备治疗糖尿病肾病药物中的用途
KR101486147B1 (ko) * 2013-07-09 2015-01-23 주식회사 엘지생활건강 Tslp 분비 저해능 및 이에 의한 알러지성 질환의 개선능을 가지는 조성물
HK1249057A1 (zh) * 2015-07-01 2018-10-26 安成生物科技股份有限公司 双醋瑞因或大黄酸局部用制剂及其用途

Also Published As

Publication number Publication date
EP4147694A1 (en) 2023-03-15
JP2018523687A (ja) 2018-08-23
JP2021121605A (ja) 2021-08-26
CN108349867A (zh) 2018-07-31
RU2729066C2 (ru) 2020-08-04
CN108349867B (zh) 2021-03-09
JP2023078360A (ja) 2023-06-06
AU2016308121A1 (en) 2018-03-01
RU2018109237A (ru) 2019-09-19
EP3337782A1 (en) 2018-06-27
CA2994987A1 (en) 2017-02-23
US10195170B2 (en) 2019-02-05
EP3337782A4 (en) 2019-04-03
IL257379A (en) 2018-04-30
RU2018109237A3 (https=) 2019-12-31
TWI743047B (zh) 2021-10-21
AU2021200117A1 (en) 2021-03-18
TW201717927A (zh) 2017-06-01
MX2018002049A (es) 2018-06-15
AU2021200117B2 (en) 2023-09-28
HK1254388A1 (zh) 2019-07-19
WO2017031161A1 (en) 2017-02-23
BR112018003212A2 (en) 2018-09-25
CA2994987C (en) 2023-09-26
KR20180037261A (ko) 2018-04-11
US20170049733A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
JP6887987B2 (ja) Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ
US10653669B2 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
EP3818081A1 (en) Compositions and methods for treating inflammasome related diseases or conditions
AU2018222881A1 (en) Method for treating drug resistant cancer
CN105579439A (zh) 辐射减轻性药物制剂
KR20250089568A (ko) 진통제 폴리펩티드
TW200410677A (en) Method of treating osteoarthritis
JPWO2008111296A1 (ja) 角化の亢進に起因する皮膚疾患の予防及び治療のための医薬
US20080269310A1 (en) Synergistic Combinations
CA3022781A1 (en) Methods and formulations for treatment and/or prevention of blood-associated disorders
JP2021533128A (ja) 神経変性障害を治療するための方法
RU2716164C2 (ru) Стабильные композиции нейроактивных пептидов
HK1254388B (zh) 用於抑制asc的表达、nlrp3的表达和/或nlrp3炎性复合体的形成的双醋瑞因或其类似物
JP2019023235A (ja) アミロイド線維形成の抑制又は阻害剤
Zhang et al. COX-2/sEH Dual Inhibitor PTUPB Inhibits Epithelial-Mesenchymal Transformation of Alveolar Epithelial Cells by Suppressing TGF-β1-Smad2/3 Signaling Pathway
WO2026030527A1 (en) Formulations for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210519

R150 Certificate of patent or registration of utility model

Ref document number: 6887987

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250